Exploring Darunavir, Rilpivirine and Etravirine As Potential Therapies for Bladder Cancer: Efficacy and Synergistic Effects

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2024 Mar 28

PMID 38540260

Authors

Mariana Pereira

Nuno Vale

Affiliations

Soon will be listed here.

Abstract

This research explores the therapeutic efficacy of Darunavir (DRV), Rilpivirine (RPV), and Etravirine (ETV) against UM-UC-5 bladder cancer cells, addressing the critical need for innovative treatments in bladder cancer research. Through a comprehensive assessment of their individual and combined effects across diverse time intervals, ETV emerges as the most potent drug, with a lowest IC of 5.9 µM, closely followed by RPV (lowest IC of 9.6 µM), while DRV exhibits the least effectiveness (lowest IC of 25.6 µM). Notably, a significant synergistic effect is evident in the ETV and RPV combination, especially at 48 and 72 h for low concentrations. Synergies are also observed with ETV and DRV, albeit to a lesser extent and primarily at 48 h. Conversely, the DRV and RPV combination yields minimal effects, predominantly additive in nature. In summary, this pre-clinical investigation underscores the promising therapeutic potential of ETV and RPV, both as standalone treatments and in combination, hinting at repurposing opportunities in bladder cancer therapy, which could give a new treatment method for this disease that is faster and without as severe side effects as anticancer drugs. These findings represent a substantial stride in advancing personalized medicine within cancer research and will be further scrutinized in forthcoming studies.

References

Mobley A, Zhang S, Bondaruk J, Wang Y, Majewski T, Caraway N . Aurora Kinase A is a Biomarker for Bladder Cancer Detection and Contributes to its Aggressive Behavior. Sci Rep. 2017; 7:40714. PMC: 5244380. DOI: 10.1038/srep40714. View

Abdel-Naser M, Altenburg A, Zouboulis C, Wollina U . Schistosomiasis (bilharziasis) and male infertility. Andrologia. 2018; 51(1):e13165. DOI: 10.1111/and.13165. View

Cordova-Bahena L, Sanchez-Alvarez A, Ruiz-Moreno A, Velasco-Velazquez M . Repositioning of Etravirine as a Potential CK1ε Inhibitor by Virtual Screening. Pharmaceuticals (Basel). 2022; 15(1). PMC: 8778358. DOI: 10.3390/ph15010008. View

Hawash M . Highlights on Specific Biological Targets; Cyclin-Dependent Kinases, Epidermal Growth Factor Receptors, Ras Protein, and Cancer Stem Cells in Anticancer Drug Development. Drug Res (Stuttg). 2019; 69(9):471-478. DOI: 10.1055/a-0898-7347. View

Al-Janabi A . Repurposing of Tamoxifen Against the Oral Bacteria. Turk J Pharm Sci. 2021; 18(1):68-74. PMC: 7957305. DOI: 10.4274/tjps.galenos.2019.23500. View

Spagnuolo V, Castagna A, Lazzarin A . Darunavir for the treatment of HIV infection. Expert Opin Pharmacother. 2018; 19(10):1149-1163. DOI: 10.1080/14656566.2018.1484901. View

Cui X, Shen D, Kong C, Zhang Z, Zeng Y, Lin X . NF-κB suppresses apoptosis and promotes bladder cancer cell proliferation by upregulating survivin expression in vitro and in vivo. Sci Rep. 2017; 7:40723. PMC: 5282527. DOI: 10.1038/srep40723. View

Guo H, Zhu Q, Yu X, Merugu S, Mangukiya H, Smith N . Tumor-secreted anterior gradient-2 binds to VEGF and FGF2 and enhances their activities by promoting their homodimerization. Oncogene. 2017; 36(36):5098-5109. DOI: 10.1038/onc.2017.132. View

Palacios J, Yildiz A, Young A, Taylor M . Tamoxifen for bipolar disorder: Systematic review and meta-analysis. J Psychopharmacol. 2019; 33(2):177-184. DOI: 10.1177/0269881118822167. View

10.

Pereira M, Vale N . Repurposing Alone and in Combination of the Antiviral Saquinavir with 5-Fluorouracil in Prostate and Lung Cancer Cells. Int J Mol Sci. 2022; 23(20). PMC: 9603134. DOI: 10.3390/ijms232012240. View

11.

Kopparapu P, Boorjian S, Robinson B, Downes M, Gudas L, Mongan N . Expression of VEGF and its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer. Anticancer Res. 2013; 33(6):2381-90. View

12.

Gazzola L, Cicconi P, Ripamonti D, Di Filippo E, Gustinetti G, Di Biagio A . Efficacy and safety of darunavir/ritonavir plus etravirine dual regimen in antiretroviral therapy-experienced patients: a multicenter clinical experience. HIV Clin Trials. 2014; 15(4):140-50. DOI: 10.1310/hct1504-140. View

13.

Islam S, Teo T, Kumarasiri M, Slater M, Martin J, Wang S . Combined and Evidence Supporting an Aurora A Kinase Inhibitory Role of the Anti-Viral Drug Rilpivirine and an Anti-Proliferative Influence on Cancer Cells. Pharmaceuticals (Basel). 2022; 15(10). PMC: 9607353. DOI: 10.3390/ph15101186. View

14.

Ferro M, Falagario U, Barone B, Maggi M, Crocetto F, Busetto G . Artificial Intelligence in the Advanced Diagnosis of Bladder Cancer-Comprehensive Literature Review and Future Advancement. Diagnostics (Basel). 2023; 13(13). PMC: 10340656. DOI: 10.3390/diagnostics13132308. View

15.

Paul S, Dutta Chowdhury K, Dey S, Paul A, Haldar R . Exploring the possibility of drug repurposing for cancer therapy targeting human lactate dehydrogenase A: a computational approach. J Biomol Struct Dyn. 2022; 41(19):9967-9976. DOI: 10.1080/07391102.2022.2158134. View

16.

Mou P, Yang E, Shi C, Ren G, Tao S, Shim J . Aurora kinase A, a synthetic lethal target for precision cancer medicine. Exp Mol Med. 2021; 53(5):835-847. PMC: 8178373. DOI: 10.1038/s12276-021-00635-6. View

17.

Pereira M, Vale N . Evolution of Antiretroviral Drug Rilpivirine and Approach to Oncology. Int J Mol Sci. 2023; 24(3). PMC: 9917964. DOI: 10.3390/ijms24032890. View

18.

Klimowski L, Garcia B, Shabanowitz J, Hunt D, Virshup D . Site-specific casein kinase 1epsilon-dependent phosphorylation of Dishevelled modulates beta-catenin signaling. FEBS J. 2006; 273(20):4594-602. DOI: 10.1111/j.1742-4658.2006.05462.x. View

19.

Pushpakom S, Iorio F, Eyers P, Jane Escott K, Hopper S, Wells A . Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2018; 18(1):41-58. DOI: 10.1038/nrd.2018.168. View

20.

Montano M, Chagomerana M, Borok M, Painschab M, Uldrick T, Bender Ignacio R . Impact of Antiretroviral Therapy on Cancer Treatment Outcomes among People Living with HIV in Low- and Middle-Income Countries: a Systematic Review. Curr HIV/AIDS Rep. 2021; 18(2):105-116. PMC: 10227634. DOI: 10.1007/s11904-021-00542-5. View